



King's Research Portal

DOI:

[10.1016/j.jamda.2018.06.007](https://doi.org/10.1016/j.jamda.2018.06.007)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Veronese, N., Stubbs, B., Volpato, S., Zuliani, G., Maggi, S., Cesari, M., Lipnicki, D. M., Smith, L., Schofield, P., Firth, J., Vancampfort, D., Koyanagi, A., Pilotto, A., & Cereda, E. (2018). Association Between Gait Speed With Mortality, Cardiovascular Disease and Cancer: A Systematic Review and Meta-analysis of Prospective Cohort Studies. *Journal Of The American Medical Directors Association*. <https://doi.org/10.1016/j.jamda.2018.06.007>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **ASSOCIATION BETWEEN GAIT SPEED WITH MORTALITY, CARDIOVASCULAR**
2 **DISEASE AND CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS**
3 **OF PROSPECTIVE COHORT STUDIES**
4

ABSTRACT

Objectives: Slow gait speed may be associated with premature mortality, cardiovascular disease (CVD) and cancer, although a comprehensive meta-analysis is lacking. In this systematic review and meta-analysis, we explored potential associations between gait speed and mortality, incident CVD and cancer.

Design: A systematic search in major databases was undertaken from inception until March 15th 2018 for prospective cohort studies reporting data on gait speed and mortality, incident CVD and cancer.

Setting and Participants: all available.

Measures: The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs), based on the model with the maximum number of covariates for each study between gait speed (categorized as decrease in 0.1 m/s) and mortality, incident CVD and cancer were meta-analysed with a random-effects model.

Results: Among 7,026 papers, 44 articles corresponding to 48 independent cohorts were eligible. The studies followed-up a total of 101,945 participants (mean age 72.2 years; 55% women) for a median of 5.4 years. After adjusting for a median of 9 potential confounders and the presence of publication bias, each reduction of 0.1 m/s in gait speed was associated with a 14% increased risk of earlier mortality (45 studies; HR=1.12; 95% CI: 1.09-1.14; $I^2=90\%$) and 8% increased risk of CVD (13 studies; HR=1.08; 95%CI: 1.03-1.13; $I^2=81\%$), but no relationship with cancer was observed (HR=1.00; 95%CI: 0.97-1.04; $I^2=15\%$).

Conclusion/implications: Slow gait speed may be a predictor of mortality and CVD in older adults. Since gait speed is a quick and inexpensive measure to obtain our study suggests that it should be routinely used and may help identify people at risk of premature mortality and CVD.

Key words: gait speed; mortality; cardiovascular disease; cancer; meta-analysis.

INTRODUCTION

The speed at which someone walks (gait speed) is an important indicator of a their functional status¹. An increasing body of research suggests that, among older people, slow gait speed is an important predictor of a range of adverse health outcomes²⁻⁶. Since gait speed is a quick, inexpensive and reliable measure of functional capacity⁷, it is widely recorded by physical therapists and other clinicians⁸ to assess the functioning of healthy¹ or disease-affected⁹ individuals.

There is a particular interest in the relationship between gait speed and mortality. Cooper et al.¹⁰ reported that slow gait speed was associated with a significantly increased mortality risk in five studies. In a seminal paper, which was not informed by a systematic review, data pooled from nine cohorts showed that faster gait speed was consistently associated with later survival in older adults¹¹. More recently, a systematic review of the literature with meta-analysis¹² reported that slow gait speed was associated with a significant higher risk of death in 12,901 participants older than 65 years. Whilst these studies have advanced our knowledge regarding gait speed and mortality, one was limited to only older people¹², whilst another only adjusted for three potential confounders¹⁰ a further was not informed by a systematic review¹¹, thus offering an incomplete picture of the total evidence base on this topic.

In addition, an increasing body of research highlighted the importance of slow gait speed as prognostic factor for other outcomes such as cancer¹³ or cardiovascular disease (CVD)¹⁴. Both CVD and cancer are the most important (and partially preventable) causes of death in industrialized countries¹⁵. Thus, to understand if slow gait speed is associated with higher incidence of CVD and cancer could be of interest. To the best of our knowledge, only one systematic review and meta-analysis has reported data regarding slow gait speed and CVD, but these findings were limited to patients affected by peripheral artery disease at baseline¹⁶. In addition, no data are available regarding the association between slow gait speed and incident cancer, but it could be of importance

55 to know if gait speed may provide additional prognostic information to improve life expectancy
56 estimation and management decisions in cancer patients.

57

58 Given this background, we aimed to investigate the association between slow gait speed and
59 mortality, taking in account different population settings and conditions. Moreover, we aimed to
60 investigate the potential association between gait speed and incident CVD and cancer.

61

METHODS

This systematic review was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] criteria¹⁷ and the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] statement.¹⁸ The protocol of this systematic review and meta-analysis pre-conceived, but not published and is available upon request to the corresponding author.

Search strategy

The published literature was searched using key words for the concepts of gait speed, risk, mortality/death/survival, CVD, and cancer until March 15th, 2018. The search strategies were established using a combination of standardized terms and key words. The search strategy used in PubMed was reported in **Supplementary Table 1** and run in the other databases (Embase, PsycINFO and the Cochrane Library). Two investigators (NV, BS) independently conducted an electronic literature search and inconsistencies were resolved by consensus with a third author (SM).

References of articles included in the analysis and of others relevant to the topic were hand-searched to identify additional, potentially relevant publications. Conference abstracts were also considered. If we encountered a conference abstract with potentially relevant data, we contacted the authors up to four times over a month period to enable inclusion and acquire the variables of interest.

Study selection

We only considered studies that: a) had a prospective design; b) reported information regarding gait speed measured by trained health personnel; c) reported data on incident mortality, CVD, or cancer determined via medical records, hospital records, confirmed physician-based diagnosis or via self-report or confirmed by relatives in the case of death).

88 Studies were excluded if they: a) did not report data regarding gait speed or the outcomes of interest;
89 b) reported data regarding transitions in gait speed over a follow-up period and outcomes of interest;
90 c) reported gait speed as self-reported information; d) reported data as odds ratios, OR (in this case,
91 the authors were contacted at least 4 times in a month to obtain the corresponding hazard ratios, HRs).

92

93 *Data extraction*

94 To be included in the quantitative synthesis, studies had to provide data on risk estimates for death,
95 any type of CVD or for specific CVD or cancer as HRs, together with precision estimates (95%
96 confidence interval [95% CI]). Two authors (NV, EC) independently recorded data extracted from the
97 selected studies into a standardized Microsoft Excel spreadsheet. Any disagreement was resolved by
98 consensus with a third author (BS).

99

100 The following information was extracted: i) study characteristics; ii) study setting (e.g., community);
101 iii) main condition (e.g. frailty, general, CVD , etc.); iv) demographic characteristics of the whole
102 population (percentage of women and mean age); v) type and number of adjustments used in the
103 multivariate analyses; vi) duration of follow-up; vii) distance (in meters) over which gait speed was
104 recorded. When two or more studies represented the same cohort, the largest study was included.

105

106 *Outcomes*

107 The primary outcome was all-cause mortality analyzed through the adjusted HRs from the model
108 with the maximum number of covariates in each study. This outcome was also analyzed according to
109 settings and any medical conditions present at baseline. The incidence of composite CVD (fatal or
110 non-fatal events) and cancer were considered as secondary outcomes.

111

112 *Assessment of study quality*

113 The Newcastle-Ottawa Scale (NOS) ^{19,20} was used to assess study quality. The NOS assigns a
114 maximum of 9 points based on three quality parameters: selection, comparability, and outcome, with
115 a cut-off of ≤ 5 being indicative of high risk of bias ¹⁹. NOS scores were initially assessed by two
116 investigators (NV, BS), and discrepancies were addressed by a joint re-evaluation of the article with
117 a third author (EC).

118

119 *Statistical analysis*

120 Analyses were performed by one investigator (NV) and checked by another researcher (EC) using
121 Comprehensive Meta-Analysis (CMA) 2 (<http://www.meta-analysis.com>).

122

123 Pooled risks of all study endpoints (all-cause mortality and incident CVD and cancer) were computed
124 for per -0.1 m/s reduction in gait speed using fully-adjusted HRs. If these estimates were not reported
125 in the original studies, they were calculated as the inverse variance-weighted mean of the logarithm
126 of HR.²¹

127

128 The random effects model was used to account for anticipated between-study heterogeneity ²². This
129 was assessed using the Chi-squared and I-squared statistics, assuming that a $p < 0.10$ for the former
130 and a value $\geq 50\%$ for the latter were indications of significant heterogeneity ²³. Whenever significant
131 heterogeneity existed and ≥ 4 studies were available, a meta-regression analysis was performed
132 examining the following pre-specified moderators: setting (community-dwelling vs. others),
133 condition (general population, presence of cancer/CVD or other medical conditions at baseline), type
134 of ascertainment (categorized as death certificates, medical/administrative data, phone calls, not
135 reported), mean age (categorized as less or more than 75 years, median value), percentage of females
136 (by the median value, 55%), number of covariates (by the median value, i.e.=9), distance walked in
137 the gait speed assessment (\leq vs. > 4 meters), and quality of the studies (by the median value, i.e.=9).
138 For incident CVD we also stratified analysis for fatal or non-fatal events.

139

140 Publication bias was assessed by visual inspection of funnel plots and using the Egger bias test ²⁴.

141 When ≥ 3 studies were available, we used the Duval and Tweedie non-parametric trim-and-fill method

142 to account for potential publication bias. Based on the assumption that the effect sizes of all the studies

143 are normally distributed around the center of a funnel plot, in the event of asymmetries, this procedure

144 adjusts for the potential effect of unpublished (trimmed) studies ²⁵.

145

RESULTS

The search identified 7,026 non-duplicated, potentially eligible studies. After excluding 6,927 papers on the grounds of a review of their titles and abstracts, 99 full-text articles were examined, and 44 articles^{11,26-69} were finally included in our meta-analysis (**eFigure 1**), with one paper¹¹ giving information for 5 cohorts in our analyses. Thus, 48 cohorts were included in the meta-analysis.

Study and patient characteristics

The 48 cohorts followed-up a total of 101,945 participants over a median of 5.4 years (range: 0.5-13.5) (**eTable 1**). These participants were on average 72.2 years old (95%CI: 59.1-85.0) and mainly women (=55 %; 95%CI: 52.0-55.6%). All the studies reported data regarding mortality, except three studies which reported data only on incident CVD^{26,42,57}, and one only on incident cancer⁴⁷.

The studies were mainly conducted in Europe (n=22). The most common setting was the community (n=35). The study samples were primarily from general population (n=26), followed by specific clinical conditions (e.g. dementia, heart failure, cancer) (n=22). The studies mainly investigated gait speed over 4 m (n=21). The quality of the studies was generally high, as shown by the median value of the NOS scale (median=9), with only six studies at high risk of bias (NOS \leq 5) (**eTable 1**).

All-cause Mortality

Figure 1 shows the association between a reduction of 0.1 m/s in gait speed and mortality including 45 cohorts with 71,308 participants and 19,294 deaths (=27.1% of the baseline population). Death was ascertained through medical/administrative data in 23 studies and through death certificates in five studies.

After adjusting for a median of 9 potential confounders (range: 0-22) and pooling data from 45 cohorts, a reduction of 0.1 m/s in gait speed was associated with an increased risk of mortality of 14%

(HR=1.14; 95% CI: 1.11-1.17; $p<0.0001$; $I^2=90\%$). The Egger's test suggested a presence of significant publication bias ($=2.21\pm0.60$; $p=0.0007$). The recalculated HR was 1.12 (95%CI: 1.09-1.14), after trimming 9 studies to the left of the mean. The fail-safe number was 7,646, indicating a large number of negative studies would be required to nullify the finding.

176

Table 1 reports the association between gait speed and mortality stratified by some possible confounders. In the studies among community-dwellers the association between a reduction in 0.1 m/s and mortality (HR=1.12; 95%CI: 1.09-1.15; $p<0.0001$; $I^2=92\%$; 31 studies) was lower than those conducted in other settings (i.e. outpatients, nursing home, hospital) (HR=1.19; 95%CI: 1.14-1.24; $p<0.0001$; $I^2=53\%$; 14 studies) (**Table 1**). There was some indication of publication bias in settings other than community (Egger's test= 2.23 ± 0.36 ; $p=0.0005$). After trimming 6 studies to the left of the mean, the adjusted HR was 1.21 (95%CI: 1.10-1.32). The fail-safe number was 2,219 for studies conducted among community dwellers and 507 in the other settings investigated.

185

When stratified by conditions, a reduction of 0.1 m/s in gait speed was associated with a higher mortality rate ranging from a HR=1.10 (95%CI: 1.01-1.20; $p=0.03$; $I^2=87\%$; 3 studies) in people affected by cancer to a HR=1.15 (95%CI: 1.11-1.17; $p<0.0001$; $I^2=71\%$; 23 studies) in the general population (**Table 1**). Studies conducted in the general population did not show evidence of any publication bias (Egger's test= 0.08 ± 0.63 ; $p=0.90$) and the fail-safe number for this outcome was 1897.

192

The meta-regression showed that none of the confounders (mean age, percentage of females, type of ascertainment, distance walked, number of covariates or quality) affected our results (**Table 1**).

195

Cardiovascular diseases

197 The association between decreasing gait speed and incident CVD is reported in **Figure 2**. Of the 13
198 studies included, 8 reported CVD related mortality as an outcome^{27,41,43,57,62-65}, two a composite
199 outcome^{31,44}, one the onset of coronary heart disease²⁶, one stroke⁴² and one hospitalization for heart
200 failure³⁸.

201 After adjusting for a median of 14 potential confounders (range: 9-22), each reduction of 0.1 m/s in
202 gait speed was associated with a higher risk of fatal or non-fatal (composite) CVD by 13% (HR=1.13;
203 95%CI: 1.08-1.18; $p<0.0001$; $I^2=81\%$). There was some evidence of publication bias (Egger's test:
204 2.92 ± 0.76 ; $p=0.003$) and, after trimming 4 studies to the left of the mean, the recalculated HR was
205 1.08 (95%CI: 1.03-1.13). The fail-safe number for this outcome was 371.

206

207 Among the moderators for the incidence of CVD investigated, studies using CVD related death as
208 the outcome reported a HR of 1.19 (95%CI: 1.10-1.29), even if no moderator (setting, main condition,
209 mean age, quality, number of covariates, type of outcome) explained any heterogeneity of our
210 findings.

211

212 *Cancer*

213 Four studies reported data regarding a reduction in gait speed and incidence of cancer (three regarding
214 overall cancer mortality^{41,62,64} and one regarding incident breast cancer⁴⁷) including a total of 20,717
215 participants and 1,087 events (=5.2%). After adjusting for a median of 17 potential confounders
216 (range: 13-21), each reduction in 0.1 m/s in gait speed was not associated with the risk of cancer
217 (HR=1.00; 95%CI: 0.97-1.04; $p=0.97$; $I^2=15\%$; **Figure 2**). For this outcome, publication bias was not
218 evident (Egger's test: 1.53 ± 0.88 ; $p=0.22$).

219 Similar findings were evident for cancer related mortality (3 studies; HR=1.02; 95%CI: 0.95-1.09;
220 $I^2=35\%$).

221

DISCUSSION

In this meta-analysis, including 48 cohorts and more than 100,000 participants, we found that slow gait speed was associated with an increased risk of earlier mortality, incident CVD, whilst we did not observe a relationship between gait speed and incident cancer. After adjusting for multiple confounders, the risk-effect associated with a reduction of 0.1 m/s in gait speed was consistent with death and the onset of CVD, which was present after adjusting for publication bias and our additional analysis indicated that a high number of studies would be required to nullify the effects (particularly for death).

Two previous meta analyses have previously reported a significant association between slow gait speed and mortality^{10,11}. Our findings are substantially in agreement with these two papers, but our study added many other studies published in recent years and is the largest meta-analysis on this topic containing over 100,000 people. In addition, our meta-analysis included all people independently from their baseline conditions and after a systematic review of the literature. The significant overall effects of our meta-analysis are supported by consistent findings of individual studies since we found a higher risk of death across 44/48 (=92%) studies. When compared to the previous literature regarding gait speed and mortality, we would like to report several novel/important points from our meta-analysis. First, a previous large systematic review and meta-analysis was limited to only older people¹² and other outcomes of great epidemiological and clinical interest, such as cancer or CVD, were not considered. Another meta-analysis regarding gait speed and mortality included only three potential confounders¹⁰, whilst, a seminal meta-analysis regarding gait speed and mortality, was not supported by a systematic review of the literature¹¹, potentially introducing a bias. Finally, we have for the first time conducted numerous subgroup analyses such as according to the setting, population, mean age and percentage of females to better explain the findings and provide a more meaningful, targeted clinical message which was previously not available. Unfortunately, despite the large number

247 of stratification, no moderator was able to explain the heterogeneity of our findings suggesting that
248 other factors could influence our results.

249

250 The reason why slow gait speed is associated with premature death is unclear but may be explained
251 through several pathways. First, a common contributor to slow gait speed is the presence of other co-
252 morbidities (e.g. diabetes, osteoarthritis) which have also been associated with premature mortality
253 ^{15,70}. However, the original papers included in our pooled analyses were adjusted for many of these
254 confounders. Second, slow gait speed is commonly associated with endocrine dysfunction (such as
255 low testosterone levels) ⁷¹, inflammation ⁷² and oxidative stress ⁷³ and all these factors are associated
256 with higher risk of death ⁷⁴⁻⁷⁶. Next to this, gait speed may indicate difficulties with activities of daily
257 living and engaging in physical activity, restrictions within each of these have been associated with
258 increased risk of earlier death ⁷⁷. Finally, as supported by a recent meta-analysis on function and
259 mortality ⁷⁸, gait speed is a powerful predictor of death, being able to early capture the multisystemic
260 impairment associated with aging and multimorbidity. Therefore, gait speed might be an indicator of
261 functional reserve and resilience.

262

263 A similar argument can be proposed for the relationship between slow gait and CVD. Higher
264 inflammatory and oxidative stress levels are known risk factors for the onset of CVD ⁷⁹, and people
265 with endocrine abnormalities often have slow gait speed ⁸⁰. Some researchers have reported that slow
266 gait speed is associated also with sub-clinical atherosclerotic lesions⁸¹. This may explain the higher
267 incidence of CVD in people with slow gait speed. Moreover, the results of our work are in agreement
268 with recent evidence highlighting frailty as a potential CVD risk factor ⁸² and suggesting that frailty,
269 sarcopenia, malnutrition and disability are inter-connected domains⁸³. However, a possible limitation
270 of the studies investigating fatal CVD events as outcomes is that they did not adjust for the presence
271 at baseline of previous CVD. Even if the adjustment for other factors is probably sufficient (minimum

272 9), we recommend that other studies using people free from CVD or at least adjusting for this relevant
273 factor at baseline are required.

274

275 On the contrary, we did not find any association between slow gait speed and incident cancer. Whilst
276 it may be true that there is no relationship between gait speed and cancer incidence, it is also possible
277 that we failed to identify a relationship as due to inadequate statistical power, as this analysis was
278 limited to four studies and only 5.2% of the baseline population developed cancer during the follow-
279 up period – raising the possibility of type II error. Similarly to our findings Wu et al. found, in a large
280 meta-analysis in community-dwellers, that low handgrip strength is associated with a higher
281 incidence of death and CVD, but not cancer⁸⁴. Since cancer is increasing worldwide⁸⁵, to elucidate
282 whether slow gait speed is associated with higher incidence of cancer is of importance and
283 consequently other studies with larger populations and longer follow-ups are needed to clarify this
284 issue.

285

286 Whilst our paper represents a comprehensive meta-analysis of the relationship between gait speed
287 and these outcomes, it should be interpreted within its limitations. First, gait speed was assessed
288 differently across the studies included. Second, as mentioned before, we were not able to explain the
289 high level of heterogeneity found regarding mortality and CVD. Moreover, some outcomes were
290 affected by publication bias. Whilst we attempted to reduce this by attempting to include conference
291 abstracts and we adjusted our results for publication bias using the trim and fill analysis, we cannot
292 exclude the possibility that studies reporting negative or null findings may not have been published
293 and could influence our findings. Third, people not able to walk were not considered in these cohort
294 studies, but it is widely known that are at higher risk of mortality. However, this source of bias cannot
295 be addressed. Finally, we had only four studies eligible for cancer and other works are needed for this
296 outcome.

297

298 In conclusion, slow gait speed is a significant predictor of mortality and of the onset of CVD, whilst
299 no significant association was found for cancer. Since gait speed is a quick and inexpensive measure
300 to obtain, also in older and vulnerable people, our work suggests that it should be routinely used.
301 Future studies on the association between slow gait speed and cancer are warranted.
302

ACKNOWLEDGEMENTS

Conflict of interest: none. Dr. EC been a consultant and/or advisor to or has received honoraria from Nutricia, Wunder and Akern.

Study funding support: This work was not supported by any funding.

REFERENCES

1. Bohannon RW, Williams Andrews A. Normal walking speed: a descriptive meta-analysis. *Physiotherapy*. 2011;97(3):182-189.
2. Rabadi MH, Blau A. Admission ambulation velocity predicts length of stay and discharge disposition following stroke in an acute rehabilitation hospital. *Neurorehabilitation and neural repair*. 2005;19(1):20-26.
3. Veronese N, Bolzetta F, Toffanello ED, et al. Association between Short Physical Performance Battery and falls in older people: the Progetto Veneto Anziani Study. *Rejuvenation research*. 2014;17(3):276-284.
4. Menant JC, Schoene D, Sarofim M, Lord SR. Single and dual task tests of gait speed are equivalent in the prediction of falls in older people: a systematic review and meta-analysis. *Ageing research reviews*. 2014;16:83-104.
5. Veronese N, Stubbs B, Trevisan C, et al. Poor Physical Performance Predicts Future Onset of Depression in Elderly People: Pro.V.A. Longitudinal Study. *Physical therapy*. 2017;97(6):659-668.
6. Waite LM, Grayson DA, Piguet O, Creasey H, Bennett HP, Broe GA. Gait slowing as a predictor of incident dementia: 6-year longitudinal data from the Sydney Older Persons Study. *J Neurol Sci*. 2005;229-230:89-93.
7. Peel NM, Kuys SS, Klein K. Gait Speed as a Measure in Geriatric Assessment in Clinical Settings: A Systematic Review. *The Journals of Gerontology: Series A*. 2013;68(1):39-46.
8. Andrews AW, Folger SE, Norbet SE, Swift LC. Tests and measures used by specialist physical therapists when examining patients with stroke. *Journal of neurologic physical therapy : JNPT*. 2008;32(3):122-128.
9. Yoward LS, Doherty P, Boyes C. A survey of outcome measurement of balance, walking and gait amongst physiotherapists working in neurology in the UK. *Physiotherapy*. 2008;94(2):125-132.
10. Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. *BMJ (Clinical research ed)*. 2010;341:c4467-c4467.
11. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *Jama*. 2011;305(1):50-58.
12. Liu B, Hu X, Zhang Q, et al. Usual walking speed and all-cause mortality risk in older people: A systematic review and meta-analysis. *Gait & posture*. 2016;44:172-177.
13. Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. *British Journal of Cancer*. 2015;112(1):194-198.
14. Afilalo J. Frailty in Patients with Cardiovascular Disease: Why, When, and How to Measure. *Current cardiovascular risk reports*. 2011;5(5):467-472.
15. Collaborators GMAcOD. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet (London, England)*. 2016;388(10053):1459-1544.
16. Morris DR, Rodriguez AJ, Moxon JV, et al. Association of lower extremity performance with cardiovascular and all-cause mortality in patients with peripheral artery disease: a systematic review and meta-analysis. *Journal of the American Heart Association*. 2014;3(4).
17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of Clinical Epidemiology*. 2008;61(4):344-349.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS medicine*. 2009;6(7):e1000100-e1000100.
19. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. (Available from: URL: http://www.ohrica/programs/clinical_epidemiology/oxfordasp). 2012:2012-2012.

- 359 20. Luchini CS, Brendon; Solmi, Marco; Veronese, Nicola Assessing the quality of studies in meta-
360 analyses: Advantages and limitations of the Newcastle Ottawa Scale *World J Meta-Anal.* 2017;5:80-
361 84.
- 362 21. Harrison F. Getting started with meta-analysis. *Methods in Ecology and Evolution.* 2011;2(1):1-10.
- 363 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials.* 1986;7(3):177-188.
- 364 23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in medicine.*
365 2002;21(11):1539-1558.
- 366 24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
367 graphical test. *BMJ (Clinical research ed).* 1997;315(September):629-634.
- 368 25. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
369 publication bias in meta-analysis. *Biometrics.* 2000;56:455-463.
- 370 26. Yepishin IVC, R.; Ross,G; Petrovitch, H.; Abbott, R. ; Wen AW, B. ; Masaki, K. . Slow Gait Speed
371 Predicts Eight-Year Incident Coronary Heart Disease: The Honolulu Heart Program. *Journal of the*
372 *American Geriatrics Society.* 2016;S1:S9.
- 373 27. von Bonsdorff MB, Groffen DA, Vidal JS, et al. Coronary artery calcium and physical performance as
374 determinants of mortality in older age: the AGES-Reykjavik Study. *International journal of*
375 *cardiology.* 2013;168(3):2094-2099.
- 376 28. van der Holst HM, van Uden IW, Tuladhar AM, et al. Factors Associated With 8-Year Mortality in
377 Older Patients With Cerebral Small Vessel Disease: The Radboud University Nijmegen Diffusion
378 Tensor and Magnetic Resonance Cohort (RUN DMC) Study. *JAMA neurology.* 2016;73(4):402-409.
- 379 29. Toots A, Rosendahl E, Lundin-Olsson L, Nordstrom P, Gustafson Y, Littbrand H. Usual gait speed
380 independently predicts mortality in very old people: a population-based study. *Journal of the*
381 *American Medical Directors Association.* 2013;14(7):529 e521-526.
- 382 30. Taekema DG, Gussekloo J, Westendorp RG, de Craen AJ, Maier AB. Predicting survival in oldest old
383 people. *The American journal of medicine.* 2012;125(12):1188-1194 e1181.
- 384 31. Sergi G, Veronese N, Fontana L, et al. Pre-frailty and risk of cardiovascular disease in elderly men
385 and women: the Pro.V.A. study. *Journal of the American College of Cardiology.* 2015;65(10):976-
386 983.
- 387 32. Sanders JB, Bremmer MA, Comijs HC, van de Ven PM, Deeg DJ, Beekman AT. Gait Speed and
388 Processing Speed as Clinical Markers for Geriatric Health Outcomes. *The American journal of*
389 *geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.*
390 2017;25(4):374-385.
- 391 33. Roshanravan B, Robinson-Cohen C, Patel KV, et al. Slower Gait Speed is Associated with Increased
392 Mortality Risk in Chronic Kidney Disease. *Circulation.* 2016;125(Suppl 10):AP098.
- 393 34. Roshanravan B, Robinson-Cohen C, Patel KV, et al. Association between physical performance and
394 all-cause mortality in CKD. *Journal of the American Society of Nephrology : JASN.* 2013;24(5):822-
395 830.
- 396 35. Rosano C, Newman AB, Katz R, Hirsch CH, Kuller LH. Association between lower digit symbol
397 substitution test score and slower gait and greater risk of mortality and of developing incident
398 disability in well-functioning older adults. *Journal of the American Geriatrics Society.*
399 2008;56(9):1618-1625.
- 400 36. Rolland Y, Lauwers-Cances V, Cesari M, Vellas B, Pahor M, Grandjean H. Physical performance
401 measures as predictors of mortality in a cohort of community-dwelling older French women.
402 *European journal of epidemiology.* 2006;21(2):113-122.
- 403 37. Rodriguez-Pascual C, Paredes-Galan E, Ferrero-Martinez AI, et al. The frailty syndrome is associated
404 with adverse health outcomes in very old patients with stable heart failure: A prospective study in
405 six Spanish hospitals. *International journal of cardiology.* 2017;236:296-303.
- 406 38. Pulignano G, Del Sindaco D, Di Lenarda A, et al. Incremental Value of Gait Speed in Predicting
407 Prognosis of Older Adults With Heart Failure: Insights From the IMAGE-HF Study. *JACC Heart failure.*
408 2016;4(4):289-298.
- 409 39. Piovezan RD, Acosta D, Guerra M, et al. Lower Gait Speed Is Independently Associated with
410 Increased Mortality Risk among People with Dementia in Low- and Middle-Income Countries:

Results from the 10/66 Dementia Research Group Population-Based Cohort Study. *Alzheimer's & Dementia*. 2016;12(7):P582.

40. Pamoukdjian F, Lévy V, Sebbane G, et al. Slow gait speed is an independent predictor of early death in older cancer outpatients: Results from a prospective cohort study. *The journal of nutrition, health & aging*. 2017;21(2):202-206.

41. Nofuji Y, Shinkai S, Taniguchi Y, et al. Associations of Walking Speed, Grip Strength, and Standing Balance With Total and Cause-Specific Mortality in a General Population of Japanese Elders. *Journal of the American Medical Directors Association*. 2016;17(2):184 e181-187.

42. McGinn AP, Kaplan RC, Verghese J, et al. Walking speed and risk of incident ischemic stroke among postmenopausal women. *Stroke*. 2008;39(4):1233-1239.

43. McDermott MM, Tian L, Liu K, et al. Prognostic value of functional performance for mortality in patients with peripheral artery disease. *Journal of the American College of Cardiology*. 2008;51(15):1482-1489.

44. Matsuzawa Y, Konishi M, Akiyama E, et al. Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. *Journal of the American College of Cardiology*. 2013;61(19):1964-1972.

45. Lo AX, Donnelly JP, McGwin G, Jr., Bittner V, Ahmed A, Brown CJ. Impact of gait speed and instrumental activities of daily living on all-cause mortality in adults ≥ 65 years with heart failure. *The American journal of cardiology*. 2015;115(6):797-801.

46. Lipnicki DM, Crawford J, Kochan NA, et al. Risk Factors for Mild Cognitive Impairment, Dementia and Mortality: The Sydney Memory and Ageing Study. *Journal of the American Medical Directors Association*. 2017;18(5):388-395.

47. Kwan K, Chlebowski RT, McTiernan A, et al. Walking speed, physical activity, and breast cancer in postmenopausal women. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation*. 2014;23(1):49-52.

48. Kutner NG, Zhang R, Huang Y, Painter P. Gait Speed and Mortality, Hospitalization, and Functional Status Change Among Hemodialysis Patients: A US Renal Data System Special Study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2015;66(2):297-304.

49. Kon S, Canavan J, Schofield S, et al. Gait Speed as a predictor of mortality in COPD. 2015:OA4973.

50. Klepin HD, Geiger AM, Tooze JA, et al. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. *Journal of the American Geriatrics Society*. 2010;58(1):76-82.

51. Kamiya KM, T.; Matsue, Y.; Hamazaki, N.; Matsuzawa, R.; Tanaka, S.; Nozaki, K.; Maekawa, E.; Matsunaga, A.; Ako, J. Gait speed provides prognostic capability comparable to 6-min walk test in elderly patients with cardiovascular disease. *European journal of heart failure*. 2016;18 Suppl 1:152.

52. Idland G, Engedal K, Bergland A. Physical performance and 13.5-year mortality in elderly women. *Scandinavian journal of public health*. 2013;41(1):102-108.

53. Elbaz A, Sabia S, Brunner E, et al. Association of walking speed in late midlife with mortality: results from the Whitehall II cohort study. *Age (Dordrecht, Netherlands)*. 2013;35(3):943-952.

54. Dodson JA, Arnold SV, Gosch KL, et al. Slow Gait Speed and Risk of Mortality or Hospital Readmission After Myocardial Infarction in the Translational Research Investigating Underlying Disparities in Recovery from Acute Myocardial Infarction: Patients' Health Status Registry. *Journal of the American Geriatrics Society*. 2016;64(3):596-601.

55. Dallmeier DB, U.; Klenk, J.; Rothenbacher, D.; Koenig, W.; , Rapp KD, M. Sex-specific associations of gait speed with all-cause mortality in older adults –the ActiFE study. *European Geriatric Medicine*. 2016;7:S182.

56. Cheung CL, Lam KS, Cheung BM. Evaluation of Cutpoints for Low Lean Mass and Slow Gait Speed in Predicting Death in the National Health and Nutrition Examination Survey 1999-2004. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2016;71(1):90-95.

- 461 57. Chen PJ, Lin MH, Peng LN, et al. Predicting cause-specific mortality of older men living in the
462 Veterans home by handgrip strength and walking speed: a 3-year, prospective cohort study in
463 Taiwan. *Journal of the American Medical Directors Association*. 2012;13(6):517-521.
- 464 58. Cesari M, Pahor M, Lauretani F, et al. Skeletal muscle and mortality results from the InCHIANTI
465 Study. *The journals of gerontology Series A, Biological sciences and medical sciences*.
466 2009;64(3):377-384.
- 467 59. Cesari M, Cerullo F, Zamboni V, et al. Functional status and mortality in older women with
468 gynecological cancer. *The journals of gerontology Series A, Biological sciences and medical sciences*.
469 2013;68(9):1129-1133.
- 470 60. Arnau A, Espauella J, Mendez T, et al. Lower limb function and 10-year survival in population aged
471 75 years and older. *Family practice*. 2016;33(1):10-16.
- 472 61. Alfaro AC, A. C.; Escolante, S.; Humanes, S.; Amor, Z.; Yusta,, C.; García ADL, G.; Gutiérrez, G. Gait
473 speed as a predictor of mortality in a cohort of community-dwelling older Spanish adults. *Journal of*
474 *the American Geriatrics Society*. 2010;S1:S47.
- 475 62. Dumurgier J, Elbaz A, Ducimetière P, Tavernier B, Alpérovitch A, Tzourio C. Slow walking speed and
476 cardiovascular death in well functioning older adults: prospective cohort study. *BMJ (Clinical*
477 *research ed)*. 2009;339:b4460-b4460.
- 478 63. Lee WJ, Peng LN, Chiou ST, Chen LK. Physical Health Indicators Improve Prediction of Cardiovascular
479 and All-cause Mortality among Middle-Aged and Older People: a National Population-based Study.
480 *Scientific reports*. 2017;7:40427.
- 481 64. Hsu B, Merom D, Blyth FM, et al. Total Physical Activity, Exercise Intensity, and Walking Speed as
482 Predictors of All-Cause and Cause-Specific Mortality Over 7 Years in Older Men: The Concord Health
483 and Aging in Men Project. *Journal of the American Medical Directors Association*. 2018;19(3):216-
484 222.
- 485 65. Sigvardsen PE, Larsen LH, Carstensen HG, et al. Six-minute walking test and long term prognosis in
486 patients with asymptomatic aortic valve stenosis. *International journal of cardiology*. 2017;249:334-
487 339.
- 488 66. Hernandez-Luis R, Martin-Ponce E, Monereo-Munoz M, et al. Prognostic value of physical function
489 tests and muscle mass in elderly hospitalized patients. A prospective observational study. *Geriatrics*
490 *& gerontology international*. 2018;18(1):57-64.
- 491 67. Dulaney CR, McDonald AM, Wallace AS, Fiveash J. Gait Speed and Survival in Patients With Brain
492 Metastases. *Journal of pain and symptom management*. 2017;54(1):105-109.
- 493 68. Kittiskulnam P, Chertow GM, Carrero JJ, Delgado C, Kaysen GA, Johansen KL. Sarcopenia and its
494 individual criteria are associated, in part, with mortality among patients on hemodialysis. *Kidney*
495 *Int*. 2017;92(1):238-247.
- 496 69. Kano S, Yamamoto M, Shimura T, et al. Gait Speed Can Predict Advanced Clinical Outcomes in
497 Patients Who Undergo Transcatheter Aortic Valve Replacement: Insights From a Japanese
498 Multicenter Registry. *Circulation Cardiovascular interventions*. 2017;10(9).
- 499 70. Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and Mortality: A Prospective Cohort Study and
500 Systematic Review with Meta-analysis. *Seminars in arthritis and rheumatism*. 2016;46(2):160-167.
- 501 71. Krasnoff JB, Basaria S, Pencina MJ, et al. Free Testosterone Levels Are Associated with Mobility
502 Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring
503 Study. *The Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2790-2799.
- 504 72. Verghese J, Holtzer R, Oh-Park M, Derby CA, Lipton RB, Wang C. Inflammatory markers and gait
505 speed decline in older adults. *The journals of gerontology Series A, Biological sciences and medical*
506 *sciences*. 2011;66(10):1083-1089.
- 507 73. Gardner AW, Montgomery PS, Casanegra AI, Silva-Palacios F, Ungvari Z, Csiszar A. Association
508 between gait characteristics and endothelial oxidative stress and inflammation in patients with
509 symptomatic peripheral artery disease. *Age*. 2016;38(3):64.
- 510 74. Schottker B, Saum KU, Jansen EH, et al. Oxidative stress markers and all-cause mortality at older
511 age: a population-based cohort study. *The journals of gerontology Series A, Biological sciences and*
512 *medical sciences*. 2015;70(4):518-524.

- 513 75. Bonaccio M, Di Castelnuovo A, Pounis G, et al. A score of low-grade inflammation and risk of
514 mortality: prospective findings from the Moli-sani study. *Haematologica*. 2016;101(11):1434-1441.
- 515 76. Muraleedharan V, Jones TH. Testosterone and mortality. *Clinical endocrinology*. 2014;81(4):477-
516 487.
- 517 77. Daskalopoulou C, Stubbs B, Kralj C, Koukounari A, Prince M, Prina AM. Physical activity and healthy
518 ageing: A systematic review and meta-analysis of longitudinal cohort studies. *Ageing research*
519 *reviews*. 2017;38:6-17.
- 520 78. Pavasini R, Guralnik J, Brown JC, et al. Short Physical Performance Battery and all-cause mortality:
521 systematic review and meta-analysis. *BMC medicine*. 2016;14(1):215.
- 522 79. Libby P. Inflammation and cardiovascular disease mechanisms. *The American journal of clinical*
523 *nutrition*. 2006;83(2):456S-460S.
- 524 80. Nettleship JE, Jones Rd Fau - Channer KS, Channer Ks Fau - Jones TH, Jones TH. Testosterone and
525 coronary artery disease. 2009(0301-3073 (Print)).
- 526 81. Hamer M, Kivimaki M, Lahiri A, et al. Walking speed and subclinical atherosclerosis in healthy older
527 adults: the Whitehall II study. *Heart (British Cardiac Society)*. 2010;96(5):380-384.
- 528 82. Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail
529 and pre-frail older adults: results from a meta-analysis and exploratory meta-regression analysis.
530 *Ageing research reviews*. 2017;35:63-73.
- 531 83. Cereda E, Veronese N, Caccialanza R. The final word on nutritional screening and assessment in
532 older persons. *Current opinion in clinical nutrition and metabolic care*. 2018;21(1):24-29.
- 533 84. Wu Y, Wang W, Liu T, Zhang D. Association of Grip Strength With Risk of All-Cause Mortality,
534 Cardiovascular Diseases, and Cancer in Community-Dwelling Populations: A Meta-analysis of
535 Prospective Cohort Studies. *Journal of the American Medical Directors Association*. 2017;18(6):551
536 e517-551 e535.
- 537 85. Simard EP, Ward Em Fau - Siegel R, Siegel R Fau - Jemal A, Jemal A. Cancers with increasing
538 incidence trends in the United States: 1999 through 2008. 2012(1542-4863 (Electronic)).

539

540

541

FIGURE LEGEND

542

543 **Figure 1. Meta-analysis of pooled hazard ratios (HRs) of gait speed and mortality.**

544

545

546 **Figure 2. Meta-analysis of pooled hazard ratios (HRs) of gait speed and incident**

547 **cardiovascular disease and incident cancer.**